Janssen Scientific Affairs, LLC today announced the launch of JanssenMD™, a new online scientific resource for U.S. healthcare professionals seeking instant access to current information about Janssen products marketed in the U.S. The web-based application is designed for use on desktops, tablets, and smartphones and can be accessed at www.janssenMD.com.
JanssenMD™ has search functionality that enables clinicians to easily find full prescribing information, clinical trial data, and safety information about Janssen medications. It is among the first medical information websites to offer a self-service model that is accessible through mobile devices.
"JanssenMD™ was created to provide healthcare professionals with the information they need, when, where, and how they need it," said Dr. Norm Rosenthal, Chief Scientific Officer, Janssen Scientific Affairs, LLC. "This unique digital platform enables us to respond to healthcare professionals' questions with information that is current, accurate, and instantly accessible from any device they are using."
Currently, scientific Information is available for five pharmaceutical products – EDURANT® (rilpivirine), REMICADE® (infliximab), STELARA® (ustekinumab), XARELTO® (rivaroxaban), and ZYTIGA® (abiraterone acetate); over time, additional Janssen products will be added to JanssenMD™. Clicking these product names will link to the Full Prescribing Information for that product.
In addition to product information, JanssenMD™ provides access to Janssen Prescription Assistance Programs and Risk Evaluation and Mitigation (REMS) tools.
New study aims to reduce bias in AI health prediction models